Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease

A. Armuzzi, Paolo Gionchetti, Marco Daperno, Silvio Danese, Ambrogio Orlando, Maria Lia Scribano, Maurizio Vecchi, Fernando Rizzello, S. Ardizzone, Fabiana Castiglione, Massimo Claudio Fantini, Gionata Fiorino, G. Frieri, L. Neri, M. L. Scribano, G. C. Sturniolo

Research output: Contribution to journalArticle

Abstract

Crohn's Disease (CD) and Ulcerative Colitis (UC) are chronic, relapsing conditions resulting from uncontrolled inflammation of the intestinal mucosa. Both conditions are associated with significant disability and patients with CD face higher mortality rates compared to the general population. The increasing understanding of the immunological basis of the disease led to the introduction of biologic therapies targeting key pathways of the natural and adaptive immune response such as Tumor Necrosis Factor α (TNF-α) inhibitors and, more recently, integrin-receptor antagonists. Treatment with TNF-α inhibitors improved clinical and patient-reported outcomes for many patients who did not benefit from conventional therapy. However, a sizeable share of patients still face suboptimal outcomes due to primary or secondary therapy failure. With the introduction of VDZ, a biologic treatment targeting novel IBD-relevant biologic pathways, it is crucial to understand how to integrate such innovations into current clinical practice. To this end, a panel of 14 Italian experts in the management of IBD met for a roundtable discussion. Recommendations concerning the management of moderate-to-severe IBD based on experts' opinions and literature review are discussed in the present report.

Original languageEnglish
Pages (from-to)360-370
Number of pages11
JournalDigestive and Liver Disease
Volume48
Issue number4
DOIs
Publication statusPublished - Apr 1 2016

Fingerprint

Inflammatory Bowel Diseases
Crohn Disease
Tumor Necrosis Factor-alpha
Biological Therapy
Immune System Diseases
Expert Testimony
Adaptive Immunity
Therapeutics
Intestinal Mucosa
Ulcerative Colitis
Integrins
Inflammation
Mortality
vedolizumab
Population

Keywords

  • Crohn's Disease
  • Inflammatory Bowel Disease
  • Ulcerative Colitis
  • Vedolizumab

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. / Armuzzi, A.; Gionchetti, Paolo; Daperno, Marco; Danese, Silvio; Orlando, Ambrogio; Lia Scribano, Maria; Vecchi, Maurizio; Rizzello, Fernando; Ardizzone, S.; Castiglione, Fabiana; Fantini, Massimo Claudio; Fiorino, Gionata; Frieri, G.; Neri, L.; Scribano, M. L.; Sturniolo, G. C.

In: Digestive and Liver Disease, Vol. 48, No. 4, 01.04.2016, p. 360-370.

Research output: Contribution to journalArticle

Armuzzi, A, Gionchetti, P, Daperno, M, Danese, S, Orlando, A, Lia Scribano, M, Vecchi, M, Rizzello, F, Ardizzone, S, Castiglione, F, Fantini, MC, Fiorino, G, Frieri, G, Neri, L, Scribano, ML & Sturniolo, GC 2016, 'Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease', Digestive and Liver Disease, vol. 48, no. 4, pp. 360-370. https://doi.org/10.1016/j.dld.2015.12.016
Armuzzi, A. ; Gionchetti, Paolo ; Daperno, Marco ; Danese, Silvio ; Orlando, Ambrogio ; Lia Scribano, Maria ; Vecchi, Maurizio ; Rizzello, Fernando ; Ardizzone, S. ; Castiglione, Fabiana ; Fantini, Massimo Claudio ; Fiorino, Gionata ; Frieri, G. ; Neri, L. ; Scribano, M. L. ; Sturniolo, G. C. / Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. In: Digestive and Liver Disease. 2016 ; Vol. 48, No. 4. pp. 360-370.
@article{c6c822294b4d4cea8f44eae58876f6dc,
title = "Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease",
abstract = "Crohn's Disease (CD) and Ulcerative Colitis (UC) are chronic, relapsing conditions resulting from uncontrolled inflammation of the intestinal mucosa. Both conditions are associated with significant disability and patients with CD face higher mortality rates compared to the general population. The increasing understanding of the immunological basis of the disease led to the introduction of biologic therapies targeting key pathways of the natural and adaptive immune response such as Tumor Necrosis Factor α (TNF-α) inhibitors and, more recently, integrin-receptor antagonists. Treatment with TNF-α inhibitors improved clinical and patient-reported outcomes for many patients who did not benefit from conventional therapy. However, a sizeable share of patients still face suboptimal outcomes due to primary or secondary therapy failure. With the introduction of VDZ, a biologic treatment targeting novel IBD-relevant biologic pathways, it is crucial to understand how to integrate such innovations into current clinical practice. To this end, a panel of 14 Italian experts in the management of IBD met for a roundtable discussion. Recommendations concerning the management of moderate-to-severe IBD based on experts' opinions and literature review are discussed in the present report.",
keywords = "Crohn's Disease, Inflammatory Bowel Disease, Ulcerative Colitis, Vedolizumab",
author = "A. Armuzzi and Paolo Gionchetti and Marco Daperno and Silvio Danese and Ambrogio Orlando and {Lia Scribano}, Maria and Maurizio Vecchi and Fernando Rizzello and S. Ardizzone and Fabiana Castiglione and Fantini, {Massimo Claudio} and Gionata Fiorino and G. Frieri and L. Neri and Scribano, {M. L.} and Sturniolo, {G. C.}",
year = "2016",
month = "4",
day = "1",
doi = "10.1016/j.dld.2015.12.016",
language = "English",
volume = "48",
pages = "360--370",
journal = "Digestive and Liver Disease",
issn = "1590-8658",
publisher = "Elsevier B.V.",
number = "4",

}

TY - JOUR

T1 - Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease

AU - Armuzzi, A.

AU - Gionchetti, Paolo

AU - Daperno, Marco

AU - Danese, Silvio

AU - Orlando, Ambrogio

AU - Lia Scribano, Maria

AU - Vecchi, Maurizio

AU - Rizzello, Fernando

AU - Ardizzone, S.

AU - Castiglione, Fabiana

AU - Fantini, Massimo Claudio

AU - Fiorino, Gionata

AU - Frieri, G.

AU - Neri, L.

AU - Scribano, M. L.

AU - Sturniolo, G. C.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Crohn's Disease (CD) and Ulcerative Colitis (UC) are chronic, relapsing conditions resulting from uncontrolled inflammation of the intestinal mucosa. Both conditions are associated with significant disability and patients with CD face higher mortality rates compared to the general population. The increasing understanding of the immunological basis of the disease led to the introduction of biologic therapies targeting key pathways of the natural and adaptive immune response such as Tumor Necrosis Factor α (TNF-α) inhibitors and, more recently, integrin-receptor antagonists. Treatment with TNF-α inhibitors improved clinical and patient-reported outcomes for many patients who did not benefit from conventional therapy. However, a sizeable share of patients still face suboptimal outcomes due to primary or secondary therapy failure. With the introduction of VDZ, a biologic treatment targeting novel IBD-relevant biologic pathways, it is crucial to understand how to integrate such innovations into current clinical practice. To this end, a panel of 14 Italian experts in the management of IBD met for a roundtable discussion. Recommendations concerning the management of moderate-to-severe IBD based on experts' opinions and literature review are discussed in the present report.

AB - Crohn's Disease (CD) and Ulcerative Colitis (UC) are chronic, relapsing conditions resulting from uncontrolled inflammation of the intestinal mucosa. Both conditions are associated with significant disability and patients with CD face higher mortality rates compared to the general population. The increasing understanding of the immunological basis of the disease led to the introduction of biologic therapies targeting key pathways of the natural and adaptive immune response such as Tumor Necrosis Factor α (TNF-α) inhibitors and, more recently, integrin-receptor antagonists. Treatment with TNF-α inhibitors improved clinical and patient-reported outcomes for many patients who did not benefit from conventional therapy. However, a sizeable share of patients still face suboptimal outcomes due to primary or secondary therapy failure. With the introduction of VDZ, a biologic treatment targeting novel IBD-relevant biologic pathways, it is crucial to understand how to integrate such innovations into current clinical practice. To this end, a panel of 14 Italian experts in the management of IBD met for a roundtable discussion. Recommendations concerning the management of moderate-to-severe IBD based on experts' opinions and literature review are discussed in the present report.

KW - Crohn's Disease

KW - Inflammatory Bowel Disease

KW - Ulcerative Colitis

KW - Vedolizumab

UR - http://www.scopus.com/inward/record.url?scp=84960796928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960796928&partnerID=8YFLogxK

U2 - 10.1016/j.dld.2015.12.016

DO - 10.1016/j.dld.2015.12.016

M3 - Article

VL - 48

SP - 360

EP - 370

JO - Digestive and Liver Disease

JF - Digestive and Liver Disease

SN - 1590-8658

IS - 4

ER -